Related Experiment Video
Updated: Mar 14, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
23.4K
Thioredoxin Inhibitors Attenuate Platelet Function and Thrombus Formation.
Clive Metcalfe1, Anjana Ramasubramoni1, Giordano Pula2
1Oxford Molecular and Pathology Institute, South Parks Road, Oxford, OX1 3RE, United Kingdom.
Plos One
|October 8, 2016
Summary
Inhibiting the thioredoxin (Trx) system with small molecules impacts platelet function. This research reveals Trx regulates platelet receptors GPVI and GPIb, suggesting Trx inhibitors could be repurposed as antiplatelet agents.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- The thioredoxin (Trx) system, an oxidoreductase, plays crucial physiological roles.
- Imbalances in this system are linked to pathologies like cancer, driving interest in Trx inhibitors.
- Oxidoreductases are increasingly recognized for their importance in hemostasis.
Purpose of the Study:
- To investigate the effect of inhibiting the NADPH/thioredoxin reductase/thioredoxin system on platelet function and thrombosis.
- To identify potential Trx substrates on platelet surfaces using proteomics.
Main Methods:
- Utilized small molecule Trx inhibitors (PMX 464, PX-12) and proteomics (LC-MS/MS).
- Assessed platelet function, including GPVI-mediated activation and GPIb-vWF-mediated agglutination.
- Investigated effects on cell surface protein thiol oxidation states.
Main Results:
- PMX 464 and PX-12 altered thiol oxidation in platelet surface proteins.
- Key receptors GPVI and GPIb were affected, impacting platelet adhesion and activation.
- Trx inhibitors selectively inhibited GPVI activation and attenuated GPIb-vWF-mediated agglutination.
Conclusions:
- Thioredoxin plays a novel role in regulating platelet reactivity through GPVI and GPIb.
- Trx inhibition affects critical early platelet responses at sites of vascular injury.
- PMX 464 and PX-12 show potential for repurposing as antiplatelet therapies.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:22Formation of the Platelet Plug
10.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K